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choice for young patients (pts) with severe manifestations of the
disease. In this study, we analyze the results in 19 boys transplanted
in 2 BMT centers between 04/92–03/05. Age: 7 months to 14 years
(M: 2 years). All but one pt had the classical syndrome with many
serious infections (especially CMV related) or autoimmunity prior
to transplant.Stem cell source: Bone marrow from related: 9 pts or
cord blood (CB) from unrelated donors:10 pts. HLA disparities:
Bone marrow: 6/6: 7 pts and 5/6: 2 pts; CB: 6/6: 1 pt, 5/6: 6 pts and
4/6: 3 pts. Preparatory regimen: Busulfan(BU)  Cyclophospha-
mide(CY)  ATG: 17 pts; BU  Fludara: 1 pt, and BU  CY 
Thiotepa: 1 pt. GVHD prophylaxis:cyclosporine (csa)  metho-
trexate: 8 pts; csa  steroids: 10 pts, and csa  MMF: 1 pt. ATG
was added to pts receiving transplants from donors other than
HLA identical siblings. TNC infused: bone marrow 2, 3—10 
108/kg (M: 3, 08) and CB: 4, 9mdash;8,8–107/kg (6, 12).
Sixteen pts (84%) are alive between 117 to 3997 days (M: 776 days)
after SCT. All pts survived more than 28 days and were evaluable
for engraftment. Mucositis grade I-II occurred in most pts. VOD
(mild): 2 pts. Three pts died on day 34 (Unrelated CB 4/6,
pulmonary aspergilosis), day 65, and day 117 (HLA identical
siblingsmdash;CMV pneumonitis). Primary graft failure occurred
in 2 pts who received Unrelated 4/6 CB and only 1 pt is alive and
well on day 370 after the second CB infusion. This pt developed
acute (grade III) and chronic (extensive) GVHD and many other
severe viral infections. Seventeen pts engrafted and the median
time to reach ANC 	 500/ul was 22 days (10–30) and platelets 	
20.000/ul was 35 days (14–77). Acute GVHD occurred in 7/17 pts
(only one pt grade IV) and chronic GVHD in 3/16 pts (extensive
and severe). Three pts are still receiving treatment with immuno-
supressive drugs. Full donor chimerism was achieved in 15/16
surviving pts.Viral infections were frequent complications, espe-
cially in the URD cord blood transplants.We conclude that SCT in
pts with WAS has an excellent survival and should be indicated to
young pts with severe manifestations of the disease.
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EARLY HEPATIC COMPLICATION IN FIRST YEAR AFTER BONE MARROW
TRANSPLANTATION IN MAJOR THALASSEMIA PATIENTS
Iravani, M.1, Nedaeifard, L.1, Arshy, M.1, Toutounchi, M.1,
Ghavamzadeh, A.1 1Hematology-Oncology and BMT Research Center,
Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
Liver complications are one of the major causes of morbidity
and mortality following BMT. Determination of the factors of
liver injury leads to earlier diagnosis after BMT and improves
prognosis. We studied 113 major thalassemic patients who
have been transplanted from 1990–2000 in bone marrow trans-
plantation center of Shariati Hospital. Sixty-two were male and
51 were female. Twenty-seven patients were class 1, 56 were
class 2, and 30 were class 3. The median age of each class were
6.5, 6.3, and 8.7 year. Conditioning regimen consisted of busul-
fan (3.5–4 mg/Kg) and cyclophophamide (40–50 mg/Kg).For
GVHD prophylaxis we gave cyclosporine  metothoroxate.
Grade of liver ﬁbrosis was deﬁned by biopsy in all patients
before BMT. All patients and their donors tested for HBSAg,
HBSAb, HCVAb, and CMVAb with RIA method. We assessed
causes of liver dysfunction before and after transplantation and
effect of high ferritin level on liver function. Hepatic dysfunc-
tion in ﬁrst year after transplantation was seen in 86 (76%)
patients. Causes of liver dysfunction consisted of 53.1%
GVHD, 15.93% cyclosporine hepatotoxicity, 7.07% condition-
ing regimen hepatotoxicity, and VOD. In all three classes he-
patic GVHD, cyclosporine toxicity, death, and normal liver
function post BMT had signiﬁcant relation with hepatic dys-
function before BMT (P  .001). In patients with ferritin level
more than 1000, there was signiﬁcant hepatotoxicity with con-
ditioning regimen (P  .001). According to our study, hepatic
GVHD (%53.1) is the most common cause of hepatic dysfunc-
tion in all three classes.
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BOOSTING OF THYMIC T LYMPHOCYTE MATURATION AND EXPORT BY
INFUSION OF T CELL DEPLETED DONOR PERIPHERAL BLOOD STEM
CELLS TO A SCID PATIENT WITH DECLINING T LYMPHOCYTE COUNTS
AFTER HLA MISMATCH ALLOGENEIC BMT
Jacobsen, N.1, Dickmeiss, E.2, Heilmann, C.3, Madsen, H.O.2,
Svejgaard, A.2, Dupont, B.4, Ryder, L.2 1. Dept of Haematology, Rig-
shospitalet, Copenhagen, Denmark; 2. Dept of Clin Immunol, Rigshos-
pitalet, Copenhagen, Denmark; 3. Paediatric Clinic II, Rigshospitalet,
Copenhagen, Denmark; 4. Dept of Medicine and Immunol Program.
Mermorial Sloan-Kettering Cancer Center, New York, NY.
The patient was born June 1971. The diagnosis of SCID was
established at 3 months of age. Retrospective analysis revealed
JAK3 mutations compatible with autosomal recessive SCID. In
December 1971, he was treated with 3 infusions of BM aspirates,
totaling 7 107 nucleated cells from his mother’s brother, selected
because of a negative donor versus recipient MLR. Retrospective
HLA-typing revealed DRB1 and DQB1 identity but multiple class
I mismatches. No conditioning or GvHD prophylaxis was given. A
skin rash was observed 2 weeks after the ﬁrst infusion. No other
signs of GvHD occurred. The lymphocyte count was 5100 per mL
one year after transplantation, ca. 50% of the PBMC expressed the
not shared donor derived HLA class I antigens and 63% were
SRBC rosetting cells. Mitogen responses were normalized but
there was persistent absence of donor derived Rh(D) positive red
blood cells and of IgG and IgA production, whereas IgM isoag-
glutinin developed normally. Low blood T lymphocyte count was
noted in 1988. In 2000, the blood CD4 count was decreased to
200 per mL, and the CD8 count to 300 per mL. The TRECs
containing CD4 cell count was 0.02 per mL and the TRECs
containing CD8 cell count 0.03 per mL (1 to 2% of normal for
age). Bone marrow CD34 cells, peripheral blood neutrophils,
and B lymphocytes were of recipient origin, whereas the few
circulating T lymphocytes were of donor origin (microsatellite
analysis). A peripheral blood stem cell harvest was procured (De-
cember 2001) from the original donor and CD34 puriﬁed using
the CliniMACS device and the CliniMACS CD34 reagent set. The
patient received a total of 2.7  106 CD34 cells and 0.08  104
CD3 cells per kg BW. Cyclosporin was given for 3 month as
GvHD prophylaxis. No evidence of GvHD occurred. Subsequent
blood tests have shown no major change in the number of circu-
lating CD3, CD4 CD45RA, or CD8 CD45RA lymphocytes
over time. However, the number of CD4 and CD8 cells containing
TRECs increased within the 600 days after boosting to 1.5 and 2.5
per mL, respectively, (normal for recipient age). A subsequent
decline has been observed. We conclude that descendants from the
boosting donor CD34 cells were able to undergo maturation in
the thymus but a persistent take of donor derived CD34 cells was
not established.
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BUSULFEX, CYCLOPHOSPHAMIDE, THYMOGLOBULIN (BU/CY/
Thymo) AS PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (HSCT) IN CHILDREN WITH NON-
MALIGNANT DISORDERS (NMD)
Gross, T.G.1, Orchard, P.2, Termuhlen, A.M.1, Baker, K.S.2 1. Ohio
State University/Children’s Hospital, Columbus, OH; 2. University of
Minnesota, Minneapolis, MN.
Background: Graft failure and GVHD remain major causes of
failure in HSCT for children with non-malignant disorders (MND).
Oral busulfan (BU), cyclophosphamide (CY), equine antithymocyte
globulin (ATG) is a standard preparative used for children with
NMD. We present preliminary data for a preparative regimen of
Bulsufex®, cyclophosphamide, and Thymoglobulin® (BU/CY/
Thymo). The regimen was developed for ease of administrtion, es-
pecially for young children, and theorectic reduction of GVHD sec-
ondary to more in vivo T cell depletion associated with
Thymoglobulin® compared to equine ATG.Methods:The regimen
included Busulfex® [0.8 mg/kg (	12 kg) or 1.1 mg/kg (12 kg)] q6
hour  16 (dose adjusted to target AUC  1125 M-minute). Cy-
clophosphamide (50 mg/kg/day  4), Thymoglobulin® (2.5 mg/kg/
day  4) with CSA and short course MTX (or methylpredisone for
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cord blood). Results: 13 patients have been enrolled: LCH (3), HLH
(2), Wiscott-Aldrich (1), mannosidosis (2), Krabbe’s (1), sickle cell (1),
thalassemia (2), and Kostmann’s (1). Median age  2.2 yearrs (0.4–
9.1). Stem cell sources were: MSD (3), unrelated UCB (3–5/6 HLA
matched, 1–6/6 HLA matched), 6/6 unrelated marrow (5), 6/6 unre-
lated PBSC (1). Thymoglobulin®toxicities were: (1) seizure course
completed and (1) grade IV hypotension (course aborted after two
doses). No other non-hematologic grades 3–4 toxicities were ob-
served. All patients achieved 	90% stable donor chimerism with no
primary or secondary graft failure. Median ANC recovery  15 days
(11–35). Three patients died of infections before day 100. One pateint
developed acute GVHD (grade 2 skin only) and limited chronic
GVHD (the patient with aborted Thymoglobulin® course). Ten
(77%) survived with median follow-up of 410 days (90–1030). Con-
clusions: This preparative regimen is very well tolerated with to date
no graft failure and stable donor chimerism even with cord blood.
Thymoglobulin®appears to provide good in vitro T-cell depletion
with minimal GVHD. Additional patients need to be enrolled to
verify these results.
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COMBINED HOME ENZYME REPLACEMENT THERAPY AND UNRELATED
CORD BLOOD TRANSPLANT FOR HURLER’S SYNDROME (MPSI)
Khimji, I.1, Lepage, C.1, Zalesky, L.2, Jimenez, P.2, Barbouth, D.3,
Elsas, L.3, Delgado, I.3, Briery, B.3, Gordon, P.3, Kleiner, G.I.3 1.
Jackson Memorial Hospital, Miami, FL; 2. Accredo Therapeutics, Fort
Lauderdale, FL; 3. University of Miami School of Medicine, Miami, FL.
Hurler’s syndrome is caused by mutations in the 
iduronidase
gene and results in progressive deterioration of the central nervous
system. Allogeneic bone marrow transplantation before the age of
2 years halts disease progression and prolongs life. Enzyme re-
placement therapy (ERT) reduces lysosomal storage of mucopo-
lysaccharides in the liver and ameliorates extracranial manifesta-
tions of disease. In most instances, ERT occurs in a day hospital
setting. Since enzyme replacement therapy can mitigate airway and
pulmonary manifestation of MPS I, we hypothesized that ERT in
the peri-transplant period (pre-HSCT and immediately post-
HSCT) would decrease transplant related complications. We per-
formed combined ERT and HSCT in a 12 month old boy with
MPSI. The patient received his ﬁrst dose of Aldurazyme at 5
months of age, shortly after MPSI diagnosis. He had received 16
infusions prior to referral to our center. Throughout his pre-
transplant workup, the patient received ERT at the local Trans-
plant House by a visiting nurse. There were no infusion related
toxicities. The patient received a 5/6 unrelated cord blood unit and
engrafted on day12. Hyperacute GVHD was treated successfully
with high dose methylprednisolone pulse. Following engraftment,
the child received 8 additional doses of Aldurazyme. One year
following transplant, he continues to have normal urine GAGs,
normal enzyme level, and continues to have developmental im-
provements. We conclude that in this case of combined outpatient
ERT infusion with HSCT, pre- and post-transplant ERT does not
interfere with engraftment or developmental improvements.
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BONE MARROW TRANSPLANTATION IN A CHILD WITH TYPE C OF
NIEMANN-PICK DISEASE (SECOND CASE IN THE WORLD)
Iravani, M.1, Nedaeifard, L.1, Alimoghaddam, K.1, Mousavi, A.1,
Karimi, M.1, Ghavamzadeh, A.1 1Hematology-Oncology and BMT
Research Center, Tehran University of Medical Sciences, Tehran, Islamic
Republic of Iran.
Niemann-Pick Disease Type C (NPC) is a lysosomal storage
disease caused by an error in cellular trafﬁcking of exogenous
cholesterol resulting in accumulation of unesteriﬁed cholesterol.
Hematopoietic stem cell transplantation for Niemann-Pick disease
is considered experimental, investigational, and unproven. We
report a 4-years 7 and months old girl with Niemann-Pick type C
disease who received an allogeneic BMT. Her disease presented
with prolonged neonatal icter, hepatosplenomegaly, failure to
thrive, and progressive neurodevelopmental delay from 2 years
ago. Bone marrow biopsy revealed abundant lipid-ﬁlled foamy
macrophages. Her serum sphingomyelinase assey was normal. She
received hematopoietic stem cells from a healthy HLA-identical
female sibling, 19 year old, donor. She had neutrophil recovery
(WBC0.5 109/L) at day 17 and platelet recovery (platelet	 20
109/L) at day 33 after transplantation. She had grade 1 skin
GVHD. She had no serious infection or complication and was
discharged after 38 days. Full engraftment was evidenced by re-
gression of the hepatosplenomegaly, markedly reduced foamy mac-
rophage inﬁltration in bone marrow, and STR-PCR of 90% (Short
Tandem Repeat-polymerase chain reaction) at day 30. She has not
had any serious problems except blood transfusion twice because of
anemia, since transplantation 3 months ago. Her donor has shown
symptoms of Multiple Sclerosis disease two months after trans-
plantation. Follow-up will show the long term effect of BMT on
her disease and neurocognitive development.
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CHEDIAK-HIGASHI SYNDROME: COMPLETE ENGRAFTMENT AFTER
DOCUMENTED CHIMERISM
Ikeda, A.K.1, Roberts, R.L.1, Campbell, K.J.1, Cheng, J.C.1,
Moore, T.B.1 1Mattel Children’s Hospital at UCLA, Los Angeles, CA.
We describe a 7 year old male with a history of Chediak-Higashi
syndrome who received a matched unrelated cord stem cell trans-
plantation in the accelerated phase and achieved complete donor
engraftment after initial partial chimerism. Chediak-Higashi syn-
drome is a rare autosomal disease characterized by partial oculo-
cutaneous albinism, recurrent bacterial infections, mild bleeding
diatheses, and both central and peripheral neuropathies. In late
childhood, these patients develop an accelerated phase character-
ized by pancytopenia, hepatosplenomegaly, and lymphocytic inﬁl-
trates. Death associated with the accelerated phase is secondary to
infection and hemorrhage. The diagnosis of Chediak-Higashi syn-
drome is made by microscopic visualization of the giant cytoplas-
mic granules in leukocytes or abnormal giant melanosomes in hair
shafts. Curative treatment entails bone marrow transplantation.
Hematopoietic chimeras have been documented with clinical im-
provement, particularly being free of the accelerated phase. Our
patient demonstrated chimerism at 30 days post-transplantation.
The DNA ﬁngerprinting analysis at this time showed 30% donor
and 70% recipient cells in the marrow. The neutrophils on the
peripheral blood smear, which contained large purplish inclusion
bodies, were far fewer than the number of normal neutrophils. At
day 77, the peripheral smear showed normal neutrophils and no
granulated leukocytes. Repeat bone marrow biopsy at 84 days
post-transplant showed complete engraftment; 90% donor mar-
row. Although hematopoietic chimerism may result in signiﬁcant
clinical improvement of patients with Chediak-Higashi, there may
be further self-selection for normal marrow cells over abnormal
cells even after the initial engraftment of bone marrow transplan-
tation.
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UNRELATED DONOR UMBILICAL CORD BLOOD TRANSPLANTATION IN
TWO CHILDREN WITH AMEGAKARYOCYTIC THROMBOCYTOPENIA
WITH RADIO-ULNAR SYNOSTOSIS
Staba, S.L.1, Sola, M.C.1, William, S.B.1 1University of Florida,
Gainesville, FL.
Congenital amegakaryocytic thrombocytopenia (CAMT) with
proximal radio-ulnar synostosis is a rare autosomal dominant dis-
order of thrombopoiesis and forearm abnormality. Four children
have previously been described in the literature, some with an
identiﬁed mutation of the HoxA11 gene. The fathers of the pre-
viously reported children had skeletal abnormalities, however nor-
mal platelet counts. We describe 2 children from the same family
who had radio-ulnar synostosis and CAMT and subsequently un-
derwent unrelated donor umbilical cord blood transplant (UCBT).
The mother has radio-ulnar synostosis without any hematologic
ﬁndings. Both children lack HOXA11 mutations and demonstrated
proximal radio-ulnar sysnostosis. The ﬁrst child had thrombocy-
topenia at birth, with a bone marrow initially showing normal
cellularity with signiﬁcantly decreased megakaryocytes. She pro-
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